Evogene Ltd. EVGN
NASDAQ
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -1.77M | -5.31M | -4.46M | -2.59M | -3.98M |
| Total Depreciation and Amortization | 132.00K | 263.00K | 197.00K | 310.00K | 661.00K |
| Total Amortization of Deferred Charges | 0.00 | 334.00K | 330.00K | 326.00K | -- |
| Total Other Non-Cash Items | -412.00K | 2.26M | 351.00K | -1.65M | 530.00K |
| Change in Net Operating Assets | 74.00K | -233.00K | 1.28M | -1.58M | -1.52M |
| Cash from Operations | -1.97M | -2.69M | -2.30M | -5.18M | -4.32M |
| Capital Expenditure | -9.00K | -6.00K | -1.00K | -121.00K | -216.00K |
| Sale of Property, Plant, and Equipment | 89.00K | 47.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4.54M | 10.22M | -988.00K | -2.32M | 3.86M |
| Cash from Investing | 4.62M | 10.26M | -989.00K | -2.45M | 3.64M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -92.00K | -133.00K | -82.00K | -146.00K | -211.00K |
| Issuance of Common Stock | 805.00K | 0.00 | -- | -- | 8.07M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.55M | -123.00K | -52.00K | -13.00K | -58.00K |
| Cash from Financing | -1.84M | -256.00K | 4.15M | -159.00K | 7.80M |
| Foreign Exchange rate Adjustments | -5.00K | 9.00K | 45.00K | -20.00K | -28.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 805.00K | 7.33M | 834.00K | -7.81M | 7.10M |